Altevax is developing a powerful pioneering immunotherapy technology against cancer. Its patented melanin-based technology has been proven in pre-clinical trials to boost an antigen-specific immune response with Cytotoxic T-lymphocytes (CD8+ Killer T cells), the body’s most powerful defenders. The Altevax immunotherapy technology works with a wide range of peptides. The Altevax technology is complementary to other anti-cancer immune technologies, such as anti PD1s.
Altevax is developing an immunotherapy against glioblastoma, currently in advanced pre-clinical development, with Phase 1/2a expected in early 2024.
Altevax's partnership with Assistance Publique Hôpitaux de Paris and other research institutions enables it to leverage their resources and accelerate clinical trials.
Company Details
- Employees
- 6
- Founded
- 2016
- Address
- 55 Avenue Marceau, Paris,paris 75116,france
- Phone
- +33 9 70 40 54 00
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- altevax.com
- Keywords
- Cancer vaccines, immunotherapy, melanin, therapeutic vaccines, Peptidic vaccines, infectious diseases, CD8 Killer T cells, Immuno-oncology.
- HQ
- Paris, Paris
Altevax Biotech Questions
Altevax Biotech's helpline number is +33 9 70 40 54 00
Altevax Biotech's website is altevax.com
Altevax Biotech's LinkedIn profile is https://fr.linkedin.com/company/altevax-biotech
Altevax Biotech has
6 employees.
View email and phone details for 6
employees at Altevax Biotech.
Altevax Biotech's industry is
Pharmaceutical Manufacturing
Altevax Biotech's top competitors are
Pep-Therapy,
Pepkon,
Theravectys,
Theraonco,
Enterome,
Mnemo Therapeutics,
Ervimmune,
Abivax,
Persea,
Rosetta Omics.
Altevax Biotech's categories are Pharmaceutical Manufacturing
Altevax Biotech's founding year is 2016
